Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD44 | P16070 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.32 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29617503 | 1.00 | CD44 (0.41) | CD44CYP3A4ALDH1A1TSHRTP53 | |
| Bromide SCHEMBL2026165 | 0.98 | CD44 (0.39) | CD44CYP3A4ALDH1A1TSHRTP53 | |
| SCHEMBL1004957 | 0.82 | CYP3A4 (0.58) | CYP3A4ALDH1A1TSHRTP53TDP1 | |
| SCHEMBL146892 | 0.82 | ALDH1A1 (0.58) | CD44CYP3A4ALDH1A1TSHRTP53 | |
| SCHEMBL698002 | 0.80 | KDM4E (0.45) | CD44CYP3A4ALDH1A1TSHRTP53 | |
| Hydrochloric Acid SCHEMBL8367686 | 0.79 | CYP3A4 (0.55) | CYP3A4ALDH1A1TSHRTDP1CA1 | |
| SCHEMBL8354359 | 0.77 | NMT1 (0.39) | CD44CYP3A4ALDH1A1TP53NMT1 | |
| SCHEMBL20658401 | 0.76 | ALDH1A1 (0.40) | CD44CYP3A4ALDH1A1CA1CA2 | |
| SCHEMBL981236 | 0.75 | CYP3A4 (0.40) | CD44CYP3A4ALDH1A1TSHRNMT1 | |
| SCHEMBL17488259 | 0.75 | ALDH1A1 (0.43) | CD44CYP3A4ALDH1A1TSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 218 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2417125-B1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2015-09-09 | — | — | EP | claimed |
| US-8772280-B2 | N-aryl-2-(2-arylaminopyrimidin-4-yl)pyrrol-4-carboxamide derivatives as MPS1 kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-07-08 | — | — | US | claimed |
| WO-2010108921-A1 | N-ARYL-2-(2-ARYLAMINOPYRIMIDIN-4-YL)PYRROL-4-CARBOXAMIDE DERIVATIVES AS MPS1 KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-09-30 | — | — | WO | claimed |
| EP-1066269-B1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA NV (BE) | 2005-05-11 | — | — | EP | claimed |
| CN-1157386-C | Trisubstituted 1,3,5-triazine derivatives for treatment by HIV infections | ղɭҩҵ����˾ | 2004-07-14 | — | — | CN | claimed |
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | DAEYAERT FREDERIK FRANS DESIRE (BE) | 2002-08-22 | — | — | US | claimed |
| CN-1295566-A | Trisubstituted 1,3,5-triazine derivatives for treatment by HIV infections | JANSSEN PHARMACEUTICA NV (BE) | 2001-05-16 | — | — | CN | claimed |
| EP-1066269-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-01-10 | — | — | EP | claimed |
| US-6150360-A | ADMINISTERING TO A PATIENT SUFFERING FROM HUMAN IMMUNODEFICIENCY VIRUS INFECTION A TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVE | JANSSEN PHARMACEUTICA N.V. (BE) | 2000-11-21 | — | — | US | claimed |
| WO-1999050256-A1 | TRISUBSTITUTED 1,3,5-TRIAZINE DERIVATIVES FOR TREATMENT OF HIV INFECTIONS | JANSSEN PHARMACEUTICA N.V. (BE) | 1999-10-07 | — | — | WO | claimed |
| CN-119912402-A | FTO inhibitor and preparation method and application thereof | 中国科学院上海药物研究所 | 2025-05-02 | — | — | CN | disclosed |
| CN-116601265-B | Aromatic isothiocyanates | 默克专利股份有限公司 | 2025-02-25 | — | — | CN | disclosed |
| US-12162870-B2 | Anticancer compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-12-10 | — | — | US | disclosed |
| CN-111825558-B | Novel compound and organic light-emitting device | 乐金显示有限公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117794525-A | Anticancer compounds | 加利福尼亚大学董事会 | 2024-03-29 | — | — | CN | disclosed |
| US-4233055-A | Quaternary ammonioalkanecarboxylic acid anilides as plant growth influencing agents | CIBA-GEIGY CORPORATION (US) | 1980-11-11 | — | — | US | disclosed |
| US-4203920-A | ANTIDIARRHEAL | WILLIAM H. RORER, INC. (US) | 1980-05-20 | — | — | US | disclosed |
| US-4147804-A | ANTIARRHYTHMIA AGENTS | WILLIAM H. RORER, INC. (US) | 1979-04-03 | — | — | US | disclosed |
| US-4141718-A | ANTIGROWTH AGENTS FOR PLANTS | CIBA-GEIGY CORPORATION (US) | 1979-02-27 | — | — | US | disclosed |
| US-4060635-A | Amidinoureas for treating diarrhea | WILLIAM H. RORER, INC. (US) | 1977-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115668-A1 | Trisubstituted 1,3,5-triazine derivatives | XDH, CCR5, CXCR1 | CD44 4839/4885CYP3A4 174/4885ALDH1A1 3722/4885 |
| US-12162870-B2 | Anticancer compounds | BET1, BRD4, BICRA | CD44 4087/4885CYP3A4 3755/4885ALDH1A1 3346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.